Market Research Reports and Industry Reports

Vulvar Cancer - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Vulvar Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a womans external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 4 and 1 respectively.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Vulvar Cancer - Overview 5
Vulvar Cancer - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Vulvar Cancer - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Vulvar Cancer - Companies Involved in Therapeutics Development 17
Cutanea Life Sciences Inc 17
ISA Pharmaceuticals BV 17
MedImmune LLC 17
Ono Pharmaceutical Co Ltd 18
Oryx GmbH & Co KG 18
Vulvar Cancer - Drug Profiles 19
durvalumab + tremelimumab - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
ISA-101 - Drug Profile6
Product Description6
Mechanism Of Action6
R&D Progress6
nivolumab - Drug Profile 31
R&D Progress 32
omiganan pentahydrochloride - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Vicoryx - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Vulvar Cancer - Dormant Projects 88
Vulvar Cancer - Product Development Milestones 89
Featured News & Press Releases 89
Oct 05,011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP 89
Mar 07,011: ISA Pharma Receives 2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine 89
Jun 02,010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 89
Jun 02,010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List Of Tables

List of Tables
Number of Products under Development for Vulvar Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H2 2017 17
Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017 17
Vulvar Cancer - Pipeline by MedImmune LLC, H2 2017 18
Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 18
Vulvar Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017 18
Vulvar Cancer - Dormant Projects, H2 2017 88

Vulvar Cancer - Pipeline Review, H2 2017

Vulvar Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H2 2017, provides an overview of the Vulvar Cancer

USD 2000View Report

Vulvar Cancer - Pipeline Insight, 2017

DelveInsights, Vulvar Cancer-Pipeline Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Vulvar Cancer. The report provides a complete understanding of the pipeline activities covering

USD 1250View Report

Ovarian Cancer - Pipeline Review, H2 2017

Ovarian Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer - Pipeline Review, H2 2017, provides an overview of the Ovarian Cancer

USD 2500View Report

Pancreatic Cancer - Pipeline Review, H2 2017

Pancreatic Cancer - Pipeline Review, H2 2017Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H2 2017, provides an overview of the Pancreatic Cancer

USD 2500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Nov 2017
No. of Pages :92
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube